Leap Therapeutics Inc
LPTX2.050USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
84.95MMarket Cap
LossP/E TTM
More Details of Leap Therapeutics Inc Company
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The Company is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The Company also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Leap Therapeutics Inc Info
Ticker SymbolLPTX
Company nameCypherpunk Technologies Inc
IPO dateJan 24, 2017
CEOOnsi (Douglas E)
Number of employees52
Security typeOrdinary Share
Fiscal year-endJan 24
Address47 Thorndike Street
CityCAMBRIDGE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02142
Phone16172524343
Websitehttps://www.leaptx.com/
Ticker SymbolLPTX
IPO dateJan 24, 2017
CEOOnsi (Douglas E)
Company Executives of Leap Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
140.87K
+30.09%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
23.05K
--
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
--
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
--
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
--
Mr. Khing Oei
Mr. Khing Oei
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. William (Wil) Mcevoy
Mr. William (Wil) Mcevoy
Chief Investment Officer, Director
Chief Investment Officer, Director
--
--
Dr. Richard L. Schilsky, M.D.
Dr. Richard L. Schilsky, M.D.
Independent Director
Independent Director
--
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. William W. Li, M.D.
Dr. William W. Li, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
140.87K
+30.09%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
23.05K
--
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
--
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
--
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
--
Mr. Khing Oei
Mr. Khing Oei
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: 7 hours ago
Updated: 7 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Winklevoss Capital Management, LLC
14.62%
Severns (Sean Michael)
10.59%
Gilead Sciences Inc
9.39%
BofA Global Research (US)
2.55%
Acadian Asset Management LLC
2.18%
Other
60.66%
Shareholders
Shareholders
Proportion
Winklevoss Capital Management, LLC
14.62%
Severns (Sean Michael)
10.59%
Gilead Sciences Inc
9.39%
BofA Global Research (US)
2.55%
Acadian Asset Management LLC
2.18%
Other
60.66%
Shareholder Types
Shareholders
Proportion
Family Office
14.62%
Corporation
11.53%
Individual Investor
10.99%
Investment Advisor
6.90%
Investment Advisor/Hedge Fund
3.10%
Research Firm
2.88%
Venture Capital
1.25%
Hedge Fund
0.35%
Bank and Trust
0.01%
Other
48.38%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
109
9.06M
16.46%
-11.77M
2025Q2
120
18.70M
45.12%
-8.55M
2025Q1
140
18.85M
45.62%
-6.95M
2024Q4
134
21.35M
55.72%
-2.16M
2024Q3
140
20.83M
54.42%
+2.16M
2024Q2
141
20.87M
54.74%
+4.28M
2024Q1
149
9.36M
39.74%
-1.79M
2023Q4
154
7.72M
34.00%
-3.79M
2023Q3
169
9.36M
44.45%
-1.96M
2023Q2
173
10.09M
52.77%
+1.83M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Gilead Sciences Inc
5.32M
12.84%
--
--
Jun 30, 2025
Acadian Asset Management LLC
1.24M
2.99%
-43.42K
-3.39%
Jun 30, 2025
Beigene Ltd
1.22M
2.93%
+1.22M
--
Oct 31, 2024
The Vanguard Group, Inc.
1.16M
2.8%
-14.92K
-1.27%
Jun 30, 2025
Hightower Advisors, LLC
1.10M
2.65%
+1.05M
+2071.98%
Jun 30, 2025
Simplify Asset Management Inc
857.36K
2.07%
-93.61K
-9.84%
Jun 30, 2025
HealthCare Ventures LLC
697.23K
1.68%
+20.91K
+3.09%
Apr 21, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Simplify Health Care ETF
0.37%
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Avantis US Small Cap Equity ETF
0%
Simplify Health Care ETF
Proportion0.37%
iShares Micro-Cap ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Date
Type
Ratio
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
FAQs
Who are the top five shareholders of Leap Therapeutics Inc?
The top five shareholders of Leap Therapeutics Inc are:
Gilead Sciences Inc holds 5.32M shares, accounting for 12.84% of the total shares.
Acadian Asset Management LLC holds 1.24M shares, accounting for 2.99% of the total shares.
Beigene Ltd holds 1.22M shares, accounting for 2.93% of the total shares.
The Vanguard Group, Inc. holds 1.16M shares, accounting for 2.80% of the total shares.
Hightower Advisors, LLC holds 1.10M shares, accounting for 2.65% of the total shares.
Gilead Sciences Inc holds 5.32M shares, accounting for 12.84% of the total shares.
Acadian Asset Management LLC holds 1.24M shares, accounting for 2.99% of the total shares.
Beigene Ltd holds 1.22M shares, accounting for 2.93% of the total shares.
The Vanguard Group, Inc. holds 1.16M shares, accounting for 2.80% of the total shares.
Hightower Advisors, LLC holds 1.10M shares, accounting for 2.65% of the total shares.
What are the top three shareholder types of Leap Therapeutics Inc?
The top three shareholder types of Leap Therapeutics Inc are:
Winklevoss Capital Management, LLC
Severns (Sean Michael)
Gilead Sciences Inc
Winklevoss Capital Management, LLC
Severns (Sean Michael)
Gilead Sciences Inc
How many institutions hold shares of Leap Therapeutics Inc (LPTX)?
As of 2025Q3, 109 institutions hold shares of Leap Therapeutics Inc, with a combined market value of approximately 9.06M, accounting for 16.46% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -28.66%.
What is the biggest source of revenue for Leap Therapeutics Inc?
In --, the -- business generated the highest revenue for Leap Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
